Kezar Life Sciences to Participate in Three Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that the Company will participate in three upcoming investor conferences taking place in September:

• Event: 2023 Wells Fargo Healthcare Conference
  Location: Boston, MA
  Date/Time: Thursday, September 7, 2023, at 12:45 pm ET
  Presenter: Noreen R. Henig, M.D., Chief Medical Officer
  Format: Fireside Chat

• Event: Morgan Stanley 21^st Annual Global Healthcare Conference
  Location: New York, NY
  Date/Time: Tuesday, September 12, 2023, at 10:50 am ET
  Presenter: John Fowler, Co-Founder and Chief Executive Officer
  Format: Fireside Chat

• Event: H.C. Wainwright 25^th Annual Global Investment Conference
  Location: New York, NY
  Date/Time: Wednesday, September 13, 2023, at 12:30 pm ET
  Presenter: John Fowler, Co-Founder and Chief Executive Officer
  Format: Podium Presentation

Webcasts from the presentations will be available on the “Events & Presentations” section of the Company’s website at www.kezarlifesciences.com. Following the events, archived webcasts will be available on the Kezar website for 90 days.

About Kezar Life Sciences

Kezar Life Sciences is a clinical-stage biopharmaceutical company discovering and developing novel treatments for immune-mediated and oncologic disorders. The company is pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function to inhibit multiple drivers of disease via single, powerful targets. Zetomipzomib, its lead development asset, is a selective immunoproteasome inhibitor that has completed a Phase 2 clinical trial in lupus nephritis. This product candidate also has the potential to address multiple chronic immune-mediated diseases. KZR-261 is the first anti-cancer clinical candidate from the company’s platform targeting the Sec61 translocon and the protein secretion pathway. An open-label dose-escalation Phase 1 clinical trial of KZR-261 to assess safety, tolerability and preliminary tumor activity in solid tumors is underway. For more information, visit www.kezarlifesciences.com and follow us on LinkedIn, Facebook, Twitter and Instagram.